Seattle Genetics is already the biggest biotech in Washington state, but CEO Clay Siegall has something even bigger in mind.
“My vision is to grow Seattle Genetics into a $20 billion, $30 billion, $40 billion market cap company that’s profitable and has 1,500 or 2,000 employees with manufacturing facilities,” Siegall said in an interview with the Puget Sound Business Journal.
That kind of growth would eclipse Immunex, which had more than 1,600 employees and a market capitalization of about…
Seattle Genetics is already the biggest biotech in Washington state, but CEO Clay Siegall has something even bigger in mind.
“My vision is to grow Seattle Genetics into a $20 billion, $30 billion, $40 billion market cap company that’s profitable and has 1,500 or 2,000 employees with manufacturing facilities,” Siegall said in an interview with the Puget Sound Business Journal.
That kind of growth would eclipse Immunex, which had more than 1,600 employees and a market capitalization of about…